Highlights
- Phase 2/3 Study 302 in 519 men met all primary and key secondary endpoints, announced April 27.
- Study 207 in women, announced July 15, showed average non-vellus hair count gains of about 23 hairs per square centimeter.
- Veradermics held $819.9 million of cash, cash equivalents and marketable securities, which it expects to fund operations into 2030.
- Second quarter 2026 net loss widened to $23.5 million, or $0.58 per share, with no product revenue.
Veradermics Incorporated (NYSE:MANE) shares were trading near their 52-week high at USD 137.17 on October 21, 2026, up 7.91%. The pattern hair loss drug developer went public in February, reported male Phase 2/3 results in April, closed a follow-on offering in May, announced female study data on July 15, and filed its second quarter 2026 report on August 11.
Based in New Haven, Connecticut, Veradermics is a Delaware corporation and describes itself as a dermatologist-founded, late clinical-stage biopharmaceutical company. Its lead candidate, VDPHL01, is an oral, extended-release, non-hormonal formulation of minoxidil for men and women with pattern hair loss. The pipeline also includes VDMN for common warts, VDAA for alopecia areata and VDMC for molluscum contagiosum. The company reported 37 full-time employees at June 30, 2026, and it is an emerging growth company and smaller reporting company.
Male and Female Hair Loss Data
Study 302, a randomized, placebo-controlled Phase 2/3 trial, enrolled 519 men with mild-to-moderate pattern hair loss. Patients received VDPHL01 8.5 mg once daily, 8.5 mg twice daily or placebo. At Month 6, non-vellus target area hair count rose by an average of 30.3 hairs per square centimeter on the once-daily dose and 33.0 on the twice-daily dose, against 7.3 on placebo. The company said the trial met every primary and key secondary endpoint, with p-values below 0.0001 on the co-primary measures.
On the patient-reported measure, 48.4% of the once-daily group and 62.9% of the twice-daily group reported improved or much improved hair coverage, versus 13.4% on placebo. Overall adverse event rates were similar to placebo, with no treatment-related serious adverse events and none of cardiac origin. The most common events were peripheral edema and hypertrichosis.
Study 207 was a 49-participant open-label Phase 2 study. In women given 4.5 mg of VDPHL01 once or twice daily, the average non-vellus hair count rose 22.7 and 23.3 hairs per square centimeter at Month 6. Unlike Study 302, it was open label rather than placebo-controlled. After quarter end, it completed enrollment in Study 306, a registration-directed Phase 2/3 trial in women.
Losses Widen as Spending Rises; Financing Detail
Veradermics has no product revenue. Second quarter 2026 research and development expense was $18.6 million, up from $14.3 million, and general and administrative expense reached $10.9 million versus $1.7 million. The company tied the increase to higher stock-based compensation, pre-commercial launch preparation and public company costs. Other income, net, rose to $6.1 million on interest income, and the net loss was $23.5 million against $15.6 million. For six months, the net loss was $50.7 million and operating cash outflow was $35.7 million, leaving an accumulated deficit of $174.2 million.
Funding came from the February initial public offering, which raised $269.1 million net at $17.00 per share, and a May follow-on offering of 4,420,358 shares at $100.00 that raised $414.3 million net. A concurrent private placement of pre-funded warrants added $28.1 million net. The filing notes that management evaluated going-concern conditions given recurring losses, and concluded that existing resources will cover obligations for at least twelve months.
Funding Runway and Next Milestones
Management expects its cash, cash equivalents and marketable securities to fund operating expenses and capital expenditures into 2030, based on current plans, though it cautioned that assumptions could prove wrong and resources could run out sooner. The company expects to report topline data from Study 306 in the first half of 2027, and it is preparing for a planned new drug application for VDPHL01, which could first seek approval in men and then in women, or in both together, depending on trial timing.
The company said it expects significant losses to continue and that it will need substantial additional funding. It has never obtained regulatory approval for or commercialized a product. These statements are the company's expectations and are subject to clinical, regulatory and funding risks.






Please wait processing your request...